Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesDividends payablesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Vycor Medical (VYCO) Other Accumulated Expenses (2016 - 2025)

Vycor Medical has reported Other Accumulated Expenses over the past 15 years, most recently at $88429.0 for Q2 2025.

  • Quarterly Other Accumulated Expenses fell 44.69% to $88429.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $88429.0 through Jun 2025, down 44.69% year-over-year, with the annual reading at $157545.0 for FY2024, 3.77% up from the prior year.
  • Other Accumulated Expenses was $88429.0 for Q2 2025 at Vycor Medical, down from $126212.0 in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $2.1 million in Q1 2023 and troughed at $88429.0 in Q2 2025.
  • The 5-year median for Other Accumulated Expenses is $129937.0 (2021), against an average of $453524.4.
  • Year-over-year, Other Accumulated Expenses skyrocketed 1601.19% in 2023 and then tumbled 93.76% in 2024.
  • A 5-year view of Other Accumulated Expenses shows it stood at $126959.0 in 2021, then soared by 1432.95% to $1.9 million in 2022, then crashed by 92.2% to $151816.0 in 2023, then increased by 3.77% to $157545.0 in 2024, then plummeted by 43.87% to $88429.0 in 2025.
  • Per Business Quant, the three most recent readings for VYCO's Other Accumulated Expenses are $88429.0 (Q2 2025), $126212.0 (Q1 2025), and $157545.0 (Q4 2024).